Skip to main content
Erschienen in: Annals of Surgical Oncology 8/2013

01.08.2013 | Melanomas

S-100B: A Stronger Prognostic Biomarker than LDH in Stage IIIB–C Melanoma

verfasst von: K. P. Wevers, MD, S. Kruijff, MD, PhD, M. J. Speijers, MD, E. Bastiaannet, MSc, PhD, A. C. Muller Kobold, PhD, H. J. Hoekstra, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

In melanoma patients with nodal macrometastases, the distinction between good and poor prognosis is based on the presence of primary melanoma ulceration or metastatic involvement of 4 or more lymph nodes in the 7th edition of the American Joint Committee on Cancer (AJCC) classification. We hypothesized that biomarkers would increase the accurateness of staging in these patients. The aim was to assess and compare the prognostic impact of biomarkers S-100B and LDH and to determine the best timing of their measurement in stage IIIB–C melanoma.

Methods

A total of 119 patients underwent therapeutic lymph node dissection (TLND) for nodal macrometastases with serum S-100B and LDH level measurements preoperatively. In 75 of them, S-100B and LDH were also measured on postoperative days 1 and 2. S-100B and LDH levels on days 0, 1, and 2 were compared for their association with disease-free survival (DFS) and disease-specific survival (DSS).

Results

At a median follow-up of 17 (range 1–89) months, S-100B levels at all time points were associated with DFS. In multivariable analysis, preoperative S-100B and S-100B measured on day 2 showed the strongest association with DFS (hazard ratio [HR] 2.55, P = 0.007 and HR 3.80, P = 0.01). For DSS, the preoperative S-100B level was the strongest independent predictor (HR 2.81, P = 0.01). LDH measurements showed a significant association with DSS in univariate analysis only when measured preoperatively (HR 2.46, P = 0.01). In multivariable analysis, LDH measurement was not associated with melanoma prognosis.

Conclusions

The S-100B level measured preoperatively is, in contrast to LDH, one of the most important independent predictors of melanoma prognosis in patients undergoing TLND for nodal macrometastases.
Literatur
1.
3.
Zurück zum Zitat Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.PubMedCrossRef Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.PubMedCrossRef
4.
Zurück zum Zitat Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol. 2005;6:608–21.PubMedCrossRef Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol. 2005;6:608–21.PubMedCrossRef
5.
Zurück zum Zitat Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28:2452–9.PubMedCrossRef Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28:2452–9.PubMedCrossRef
6.
Zurück zum Zitat Kruijff S, Hoekstra HJ. The current status of S-100B as a biomarker in melanoma. Eur J Surg Oncol. 2012;38:281–5.PubMedCrossRef Kruijff S, Hoekstra HJ. The current status of S-100B as a biomarker in melanoma. Eur J Surg Oncol. 2012;38:281–5.PubMedCrossRef
7.
Zurück zum Zitat Guo HB, Stoffel-Wagner B, Bierwirth T, et al. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer. 1995;31A:1898–902.PubMedCrossRef Guo HB, Stoffel-Wagner B, Bierwirth T, et al. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer. 1995;31A:1898–902.PubMedCrossRef
8.
Zurück zum Zitat Smit LH, Korse CM, Hart AA, et al. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer. 2005;41:386–92.PubMedCrossRef Smit LH, Korse CM, Hart AA, et al. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer. 2005;41:386–92.PubMedCrossRef
9.
Zurück zum Zitat Kruijff S, Bastiaannet E, Kobold AC, et al. S-100B concentrations predict disease-free survival in stage III melanoma patients. Ann Surg Oncol. 2009;16:3455–62.PubMedCrossRef Kruijff S, Bastiaannet E, Kobold AC, et al. S-100B concentrations predict disease-free survival in stage III melanoma patients. Ann Surg Oncol. 2009;16:3455–62.PubMedCrossRef
10.
Zurück zum Zitat Bouwhuis MG, Suciu S, Kruit W, et al. Prognostic value of serial blood S100B determinations in stage IIB–III melanoma patients: a corollary study to EORTC trial 18952. Eur J Cancer. 2011;47:361–8.PubMedCrossRef Bouwhuis MG, Suciu S, Kruit W, et al. Prognostic value of serial blood S100B determinations in stage IIB–III melanoma patients: a corollary study to EORTC trial 18952. Eur J Cancer. 2011;47:361–8.PubMedCrossRef
11.
Zurück zum Zitat Tarhini AA, Stuckert J, Lee S, et al. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol. 2009;27:38–44.PubMedCrossRef Tarhini AA, Stuckert J, Lee S, et al. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol. 2009;27:38–44.PubMedCrossRef
12.
Zurück zum Zitat Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.PubMedCrossRef Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.PubMedCrossRef
13.
Zurück zum Zitat Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.PubMedCrossRef Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.PubMedCrossRef
15.
Zurück zum Zitat Poos HP, Kruijff S, Bastiaannet E, et al. Therapeutic groin dissection for melanoma: risk factors for short term morbidity. Eur J Surg Oncol. 2009;35:877–83.PubMedCrossRef Poos HP, Kruijff S, Bastiaannet E, et al. Therapeutic groin dissection for melanoma: risk factors for short term morbidity. Eur J Surg Oncol. 2009;35:877–83.PubMedCrossRef
16.
Zurück zum Zitat Bastiaannet E, Beukema JC, Hoekstra HJ. Radiation therapy following lymph node dissection in melanoma patients: treatment, outcome and complications. Cancer Treat Rev. 2005;31:18–26.PubMedCrossRef Bastiaannet E, Beukema JC, Hoekstra HJ. Radiation therapy following lymph node dissection in melanoma patients: treatment, outcome and complications. Cancer Treat Rev. 2005;31:18–26.PubMedCrossRef
17.
Zurück zum Zitat Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol. 2012;13:589–97.PubMedCrossRef Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol. 2012;13:589–97.PubMedCrossRef
18.
Zurück zum Zitat Hauschild A, Engel G, Brenner W, et al. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology. 1999;56:338–44.PubMedCrossRef Hauschild A, Engel G, Brenner W, et al. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology. 1999;56:338–44.PubMedCrossRef
19.
Zurück zum Zitat Ghanem G, Loir B, Morandini R, et al. On the release and half-life of S100B protein in the peripheral blood of melanoma patients. Int J Cancer. 2001;94:586–90.PubMedCrossRef Ghanem G, Loir B, Morandini R, et al. On the release and half-life of S100B protein in the peripheral blood of melanoma patients. Int J Cancer. 2001;94:586–90.PubMedCrossRef
20.
Zurück zum Zitat Martenson ED, Hansson LO, Nilsson B, et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol. 2001;19:824–31.PubMed Martenson ED, Hansson LO, Nilsson B, et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol. 2001;19:824–31.PubMed
21.
Zurück zum Zitat Banfalvi T, Boldizsar M, Gergye M, et al. Comparison of prognostic significance of serum 5-S-cysteinyldopa, LDH and S-100B protein in stage III–IV malignant melanoma. Pathol Oncol Res. 2002;8:183–7.PubMedCrossRef Banfalvi T, Boldizsar M, Gergye M, et al. Comparison of prognostic significance of serum 5-S-cysteinyldopa, LDH and S-100B protein in stage III–IV malignant melanoma. Pathol Oncol Res. 2002;8:183–7.PubMedCrossRef
22.
Zurück zum Zitat Egberts F, Hitschler WN, Weichenthal M, et al. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. Melanoma Res. 2009;19:31–5.PubMedCrossRef Egberts F, Hitschler WN, Weichenthal M, et al. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. Melanoma Res. 2009;19:31–5.PubMedCrossRef
23.
Zurück zum Zitat Hamberg AP, Korse CM, Bonfrer JM, et al. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res. 2003;13:45–9.PubMedCrossRef Hamberg AP, Korse CM, Bonfrer JM, et al. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res. 2003;13:45–9.PubMedCrossRef
24.
Zurück zum Zitat Lin J, Yang Q, Yan Z, et al. Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells. J Biol Chem. 2004;279:34071–7.PubMedCrossRef Lin J, Yang Q, Yan Z, et al. Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells. J Biol Chem. 2004;279:34071–7.PubMedCrossRef
25.
Zurück zum Zitat Lin J, Yang Q, Wilder PT, et al. The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma. J Biol Chem. 2010;285:27487–98.PubMedCrossRef Lin J, Yang Q, Wilder PT, et al. The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma. J Biol Chem. 2010;285:27487–98.PubMedCrossRef
26.
Zurück zum Zitat Weide B, Elsasser M, Buttner P, et al. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer. 2012;107:422–8.PubMedCrossRef Weide B, Elsasser M, Buttner P, et al. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer. 2012;107:422–8.PubMedCrossRef
27.
Zurück zum Zitat Deichmann M, Benner A, Bock M, et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol. 1999;17:1891–6.PubMed Deichmann M, Benner A, Bock M, et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol. 1999;17:1891–6.PubMed
28.
Zurück zum Zitat Egberts F, Pollex A, Egberts JH, et al. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH. Onkologie. 2008;31:380–4.PubMedCrossRef Egberts F, Pollex A, Egberts JH, et al. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH. Onkologie. 2008;31:380–4.PubMedCrossRef
29.
Zurück zum Zitat Egberts F, Kotthoff EM, Gerdes S, et al. Comparative study of YKL-40, S-100B and LDH as monitoring tools for stage IV melanoma. Eur J Cancer. 2012;48:695–702.PubMedCrossRef Egberts F, Kotthoff EM, Gerdes S, et al. Comparative study of YKL-40, S-100B and LDH as monitoring tools for stage IV melanoma. Eur J Cancer. 2012;48:695–702.PubMedCrossRef
30.
Zurück zum Zitat Garnier JP, Letellier S, Cassinat B, et al. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. Eur J Cancer. 2007;43:816–21.PubMedCrossRef Garnier JP, Letellier S, Cassinat B, et al. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. Eur J Cancer. 2007;43:816–21.PubMedCrossRef
31.
Zurück zum Zitat Diaz-Lagares A, Alegre E, Arroyo A, et al. Evaluation of multiple serum markers in advanced melanoma. Tumour Biol. 2011;32:1155–61.PubMedCrossRef Diaz-Lagares A, Alegre E, Arroyo A, et al. Evaluation of multiple serum markers in advanced melanoma. Tumour Biol. 2011;32:1155–61.PubMedCrossRef
Metadaten
Titel
S-100B: A Stronger Prognostic Biomarker than LDH in Stage IIIB–C Melanoma
verfasst von
K. P. Wevers, MD
S. Kruijff, MD, PhD
M. J. Speijers, MD
E. Bastiaannet, MSc, PhD
A. C. Muller Kobold, PhD
H. J. Hoekstra, MD, PhD
Publikationsdatum
01.08.2013
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe 8/2013
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-2949-y

Weitere Artikel der Ausgabe 8/2013

Annals of Surgical Oncology 8/2013 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.